TY  - JOUR
AU  - Cordonnier, Charlotte
AU  - Klijn, Catharina
AU  - Smith, Eric Edward
AU  - Al-Shahi Salman, Rustam
AU  - Chwalisz, Bart K
AU  - van Etten, Ellis
AU  - Muir, Ryan T
AU  - Piazza, Fabrizio
AU  - Schreiber, Stefanie
AU  - Schreuder, Floris Hbm
AU  - Selim, Magdy
AU  - Shoamanesh, Ashkan
AU  - Viswanathan, Anand
AU  - Wermer, Marieke
AU  - Zandi, Michael
AU  - Charidimou, Andreas
AU  - Greenberg, Steven M
AU  - Werring, David
TI  - Diagnosis and management of cerebral amyloid angiopathy: a scientific statement from the International CAA Association and the World Stroke Organization.
JO  - International journal of stroke
VL  - 20
IS  - 8
SN  - 1747-4930
CY  - London
PB  - Sage
M1  - DZNE-2025-01095
SP  - 949 - 967
PY  - 2025
AB  - Cerebral amyloid angiopathy (CAA) is a well-recognized and challenging disease for neurologists and other clinicians caring for the rapidly aging worldwide population. CAA is a major cause of spontaneous lobar intracerebral hemorrhage (ICH), and can also cause transient focal neurological episodes, and convexity subarachnoid hemorrhage, CAA-associated ICH has a high mortality, morbidity, and recurrence rate. CAA can affect a wide range of clinical decisions including use of antithrombotic medications, safety for anti-β-amyloid peptide (Aβ) immunotherapy, and need for anti-inflammatory or immunosuppressive treatment. We present guidelines, intended to inform the approach to individuals with suspected CAA, written on behalf of the International CAA Association and the World Stroke Organization (WSO). We cover five areas selected for their relevance to practice: (1) diagnosis, testing, and prediction of intracerebral hemorrhage risk; (2) antithrombotic agents and vascular interventions; (3) vascular risk factors and concomitant medications; (4) treatment of CAA manifestations; and (5) diagnosis and treatment of CAA-related inflammation and vasculitis. The statement has been reviewed and approved by the Executive Committee of the WSO, and the International CAA Association.
KW  - Humans
KW  - Cerebral Amyloid Angiopathy: diagnosis
KW  - Cerebral Amyloid Angiopathy: therapy
KW  - Cerebral Amyloid Angiopathy: complications
KW  - Disease Management
KW  - Cerebral Hemorrhage: etiology
KW  - Cerebral Hemorrhage: therapy
KW  - Cerebral Hemorrhage: diagnosis
KW  - Stroke: therapy
KW  - Stroke: diagnosis
KW  - Risk Factors
KW  - Fibrinolytic Agents: therapeutic use
KW  - Societies, Medical
KW  - MRI (Other)
KW  - antithrombotic (Other)
KW  - brain bleed (Other)
KW  - brain microbleeds (Other)
KW  - cerebral hemorrhage (Other)
KW  - leukoaraiosis (Other)
KW  - Fibrinolytic Agents (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40721902
DO  - DOI:10.1177/17474930251365861
UR  - https://pub.dzne.de/record/281348
ER  -